Follow
TC Biopharm are developing safer, less expensive CAR-T products which can target more cancers and save more lives. TC Biopharm do this using our integrated model which drives the development of our products through preclinical testing to the clinic. Companies mission is to develop and commercialize innovative cell-based products and to treat disease, improve patient health and Quality of Life.
TC BioPharm (Nasdaq: TCBP) is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. Established in 2014, TC Biopharm have expanded into 5 global locations and have grown to over 100 employees.
TCB was founded
TCB commenced operations in February 2014, leasing space for its lab, office and cleanroom facilities in April 2014. The initial build was completed within 6 months.
TC BioPharm received MHRA approval to initiate cancer trial
TC BioPharm received a license from MHRA to produce gamma delta T cell therapy products at its clinical manufacturing facility near Glasgow, UK.
TC BioPharm raised £1.2 million for UK cancer trial
TC BioPharm raised equity and grant funding from Scottish Enterprise and Investing Woman.
Initiation of ImmuniCell® trial
This was an adaptive clinical trial for TC BioPharm’s autologous gamma delta T cell product for melanoma, lung and kidney cancer.
Initiated phase 1 allogeneic gamma delta T cell trial
The trial, for treatment of patients suffering from Acute Myeloid Leukemia (AML), is being conducted at the Institute of Hematology and Blood Transfusion (ÚHKT) in Prague, Czech Republic.
TC BioPharm opened offices in London and Leiden
Continued growth saw TC BioPharm expand office space in London, UK and Leiden, The Netherlands.
